Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 148
- Registration Number
- NCT00241111
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 284
- Registration Number
- NCT00237159
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT00237146
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 23
- Registration Number
- NCT00226954
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00219271
- Locations
- 🇬🇷
Novartis Investigative Site, Athens, Greece
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 3
- Registration Number
- NCT00216151
- Locations
- 🇺🇸
Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
🇺🇸Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-04-17
- Target Recruit Count
- 90
- Registration Number
- NCT00215943
- Locations
- 🇺🇸
Morton Plant Hospital, Clearwater, Florida, United States
🇺🇸Fawcett Memorial Hospital, Port Charlotte, Florida, United States
🇺🇸Watson Clinic, Lakeland, Florida, United States
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Registration Number
- NCT00219219
- Locations
- 🇮🇹
Bologna, Bologna, Italy
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00219258
- Locations
- 🇨🇳
Beijing, Beijing, China
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 68
- Registration Number
- NCT00213980
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.